Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...
DNA can last for many centuries. A new DNA storage technology works in the laboratory with parallelizable writing processes ...
Report on how AI is driving market transformation - The global DNA sequencing market size is estimated to grow by USD 17.34 ...
Illumina to release new version of its flagship cancer research assay, TruSight Oncology 500 v2: San Diego Thursday, November 21, 2024, 16:00 Hrs [IST] Illumina, Inc., a global le ...
Policy changes might affect equipment prices and lab budgets in the US. Here’s what economists and industry analysts are ...
Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer ...
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will ...
The CyBio FeliX, a benchtop instrument for automated liquid handling tasks, was used to automate the HaloPlex Target ...
The Punch Newspapers on MSN7d
Institute conducts Nigeria’s first human genome sequencingThe Institute of Genomics and Global Health, formerly known as the African Centre of Excellence for Genomics of Infectious ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
The DNA sequencing company reported Q3 adjusted EPS of $1.14, which beat the Street consensus estimate by $0.26. Revenue was ...
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback